RHO and retinitis pigmentosa: In this study, we evaluated the therapeutic potential of SC79, a pharmaceutical AKT activator, in two mouse models of retinitis pigmentosa, <i>rd1</i>.GFP and <i>Rho</i>P23H.GFP.